VeriSIM Life, a San Francisco, CA-based company that is building digital animal and human simulations to avoid unnecessary drug testing in animals, raised $5.2M in funding.
The round was co-led by OCA Ventures and Serra Ventures with participation from Susa Ventures, Intel Capital, Stage Venture Partners, Village Global, Twin, and Loup Ventures.
The company intends to use the funds to optimize its models through expanded academic partnerships, grow a team to include talent in the engineering and operations space, and engage larger pharma institutions.
Led by Dr. Jo Varshney, DVM/PhD, Founder and CEO, a multi-disciplinary veterinary, along with a team of scientists and engineers in machine learning and in silico simulation, VeriSIM Life uses expertise in machine learning and engineering to produce models that serve as “digital” animals and humans.
The company is now looking to source additional opportunities with more partnering companies in the biotech and pharma space, inclusive of medical development impacting both humans and animals. With prior launches into partnerships and co-development with big companies, academia and CROs, VeriSIM Life is now positioned to continue their proof of concept and fully implement solutions for companies looking to move from bench to bedside.